CORRECTING and REPLACING NovaBay Pharmaceuticals Appoints Andrew D. Jones Chief Financial Officer
May 05 2020 - 2:05PM
Business Wire
Please replace the release with the following revised version,
which includes a change in the effective date in the first
paragraph, first sentence to May 4, 2020.
The corrected release reads:
NOVABAY PHARMACEUTICALS APPOINTS ANDREW D.
JONES CHIEF FINANCIAL OFFICER
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces
the appointment of Andrew D. Jones as Chief Financial Officer and
Treasurer, effective May 4, 2020. Mr. Jones brings to NovaBay more
than 20 years of finance and accounting experience primarily in the
life sciences industry. He replaces Lynn Christopher, who assumed
these positions on an interim basis in April 2020 and will continue
to work with NovaBay to support a smooth transition.
“We are delighted to secure a well-qualified professional to
fill our executive finance position on a permanent basis and to do
so very quickly,” said Justin Hall, NovaBay CEO. “Andrew has served
every critical function in finance and accounting from high-level
strategic planning and financial modeling, budgeting and cash
management, to technical accounting, audit and tax compliance, and
managing daily accounting operations. The breadth of his finance
and accounting experience, his background in the life sciences
industry and relevant public company accounting expertise make him
an excellent fit.”
“I look forward to serving as NovaBay’s CFO and using my entire
skillset in an executive capacity in such a dynamic environment,”
said Mr. Jones. “I’m committed to working closely with the NovaBay
team to ensure financial accountability and prudence, and to
achieve our goals for growth and business success.”
Mr. Jones most recently served as an independent consultant,
helping companies to meet their accounting and finance
requirements. He previously served as Vice President, Finance of
MyoScience, Inc., a commercial-stage medical device company,
through its acquisition by Pacira BioSciences. In this position, he
was responsible for overseeing all accounting and finance functions
as well as executive management and board-level reporting,
including strategic planning decisions that resulted in significant
revenue growth and gross margin improvements. Prior to MyoScience,
Mr. Jones was Senior Director of Finance at Armetheon, Inc., a
late-stage drug development company, and Corporate Controller of
Asante Solutions, Inc., a medical device company now known as
Bigfoot Biomedical, Inc., and Genelabs Technologies, Inc., a public
biotechnology company acquired by GlaxoSmithKline. Earlier in his
career he was a Senior Manager at PricewaterhouseCoopers providing
clients with M&A advisory and audit services. Mr. Jones holds a
BA in business administration from the University of
Washington.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, CELLERX® for the aesthetic
dermatology market, and NEUTROPHASE® for wound care market.
Forward-Looking Statements
This release contains forward-looking statements that are based
upon management’s current expectations, assumptions, estimates,
projections and beliefs. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results or achievements to be materially different and adverse from
those expressed in or implied by the forward-looking statements.
Risks relating to NovaBay’s business are detailed in NovaBay’s
latest Form 10-Q/K filings with the Securities and Exchange
Commission, under the heading “Risk Factors.” The forward-looking
statements in this release speak only as of this date, and NovaBay
disclaims any intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
Socialize and Stay informed on NovaBay’s Progress Like us
on Facebook Follow us on Twitter Connect with NovaBay
on LinkedIn Visit NovaBay’s Website
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200505005081/en/
NovaBay Contact Justin Hall CEO and General Counsel
510-899-8800 jhall@novabay.com
Investor Contact LHA Investor Relations Jody Cain
310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2023 to Sep 2024